Skip to content
Start free

Torrent Pharmaceuticals Ltd.

NSE: TORNTPHARMHealthcareDrug Manufacturers - Specialty & Generic

Last close
₹4,656.90
Day change
+₹39.80 (+0.86%)vs
Market cap
₹1.81 lakh crIndian rupees
Research updated
1 report
Follow Torrent Pharmaceuticals

Share this file

About Torrent Pharmaceuticals

Torrent Pharmaceuticals Ltd. is a leading pharmaceutical company that manufactures, markets, and distributes a diversified range of generic and branded pharmaceutical products. The company's primary function is to develop and supply medicines that cater to various therapeutic segments, including cardiovascular, central nervous system, gastrointestinal, and anti-infective therapeutics. Torrent Pharmaceuticals has established a strong presence in both domestic markets in India and international territories, with significant operations in regulated markets such as the United States and Europe. As part of its business model, Torrent focuses on research and development to drive innovation and ensure a pipeline of new products, while maintaining high standards of quality and compliance. In the global pharmaceutical industry, it plays a critical role in enhancing access to affordable medication, thereby impacting health care systems and patient outcomes worldwide.

Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Listing
NSE: TORNTPHARM
Chief executive
Mr. Sanjay Gupta
Employees
17,059
Headquarters
Ahmedabad, India
ISIN
INE685A01028
Website
torrentpharma.com

Public research

The latest report on Torrent Pharmaceuticals opens with Individual or above

Mool’s latest report on Torrent Pharmaceuticals, of 2 Oct 2026, has no section published on the open web.

With Individual or above

What the full research on Torrent Pharmaceuticals includes

Every piece of Mool’s research is built the same way: a researched evidence base, analyses that build on each other, a research model and a report with the call.

The report and Mool’s call

  • The 12-month rating and target
  • The 3-month view
  • Mool's estimates beside the street's
  • The claims the view rests on, and what would change it

The analyses, among them

  • Business model & financial foundationWhat the company does and how it makes money, its structure, five years of financials and the metrics that matter for it.
  • Future earnings & financial modelForecasts built from the drivers that move the business, by scenario, beside the street's.
  • Fundamental valuation & 12-month thesisWhat the business is worth on several methods, what the market already prices in and the 12-month thesis that follows.

The research model

The model behind the report: the company’s history, the drivers that move it, its forecasts by scenario and the valuation the 12-month target comes from.

See Mool’s call and the full research

Individual or above opens every piece of research Mool has published. A new account can start with 10 days of Pro, or of Firm on a work email address. No card needed.

Report history

Reports on Torrent Pharmaceuticals

  1. Research reportLatest

Same sector

All Healthcare companies

  • Sun Pharmaceutical Industries Ltd.

    NSE: SUNPHARMA

    Healthcare · Drug Manufacturers - Specialty & Generic

    ₹1,760.00 last close on 9 Oct 2026 +0.01%

    Research updated

  • Divi's Laboratories Ltd.

    NSE: DIVISLAB

    Healthcare · Drug Manufacturers - Specialty & Generic

    ₹9,340.00 last close on 9 Oct 2026 −0.22%

    Research updated

  • Zydus Lifesciences Ltd.

    NSE: ZYDUSLIFE

    Healthcare · Drug Manufacturers - Specialty & Generic

    ₹1,117.50 last close on 9 Oct 2026 +0.49%

    Research updated

  • Lenskart Solutions Limited

    NSE: LENSKART

    Healthcare · Medical Instruments & Supplies

    ₹677.65 last close on 9 Oct 2026 +3.62%

    Research updated

  • Emcure Pharmaceuticals Ltd.

    NSE: EMCURE

    Healthcare · Drug Manufacturers - Specialty & Generic

    ₹1,833.50 last close on 9 Oct 2026 −0.97%

    Research updated

Prices are the last close on the NSE, 9 Oct 2026. Research from Mool’s report of 2 Oct 2026; page updated 12 Oct 2026.

Mool’s research is written by AI agents and published by Mool Capital Private Limited, a SEBI-registered Research Analyst, registration INH000012449, which is responsible for it. This page shows factual company information; it carries no rating and is not investment advice for any individual. Investment in securities market are subject to market risks. Read all the related documents carefully before investing. Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors. Read the disclosures.